Individual FEV₁ Trajectories Can Be Identified from a COPD Cohort

References

• Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD 2007; 4(4):355–384. doi: 785381889 [pii].
   Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077):1645–1648.
   Google Scholar
• Nishimura M, Makita H, Nagai K, Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(1):44–52. doi: 10.1164/rccm.201106-0992OC; 10.1164/rccm.201106-0992OC.
   Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365(13):1184–1192. doi: 10.1056/NEJMoa1105482; 10.1056/NEJMoa1105482.
   Google Scholar
• Casanova C, de Torres JP, Aguirre-Jaime A, The progression of chronic obstructive pulmonary disease is heterogeneous: The experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184(9):1015–1021. doi: 10.1164/rccm.201105-0831OC; 10.1164/rccm.201105-0831OC.
   Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7:95–99. doi: 10.2147/COPD.S27480; 10.2147/COPD.S27480.
   PubMed Web of Science ®Google Scholar
• Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Qureshi H, Sharafkhaneh A, Hanania NA. Ther Adv Chronic Dis 2014; 5(5):212–227. doi: 10.1177/2040622314532862. Review.
   PubMedGoogle Scholar
• Kauppi P, Kupiainen H, Lindqvist A, Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011; 48(3):279–285. doi: 10.3109/02770903.2011.555576; 10.3109/02770903.2011.555576.
   Google Scholar
• Laitinen T, Hodgson U, Kupiainen H, Real-world clinical data identifies gender-related profiles in chronic obstructive pulmonary disease. COPD 2009; 6(4):256–262.
   Google Scholar
• Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl 1982; 159:5–20.
   PubMedGoogle Scholar
• Katajisto M, Kupiainen H, Rantanen P, Physical inactivity in COPD and increased patient perception of dyspnea. Int J Chron Obstruct Pulmon Dis 2012; 7:743–755. doi: 10.2147/COPD.S35497 [doi].
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10:59. doi: 10.1186/1465-9921-10-59; 10.1186/1465-9921-10-59.
   Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554. doi: 10.1056/NEJMoa0805800; 10.1056/NEJMoa0805800.
   Google Scholar
• Tashkin DP, Wang HJ, Halpin D, Comparison of the variability of the annual rates of change in FEV1 determined from serial measurements of the pre- versus post-bronchodilator FEV1 over 5 years in mild to moderate COPD: Results of the lung health study. Respir Res 2012; 13:70 doi: 10.1186/1465-9921-13-70; 10.1186/1465-9921-13-70.
   Google Scholar
• Tashkin DP, Li N, Halpin D, Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med 2013; 107(12):1904–1911. doi: 10.1016/j.rmed.2013.08.001 [doi].
   Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554. doi: 10.1056/NEJMoa0805800 [doi].
   Google Scholar
• Tashkin DP. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013; 19(2):116–124. doi: 10.1097/MCP.0b013e32835d8ea4; 10.1097/MCP.0b013e32835d8ea4.
   Google Scholar
• Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360(23):2445–2454. doi: 10.1056/NEJMra0804752 [doi].
   Google Scholar
• Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. Available from: www.goldcopd.org. Updated 2014. (accessed 2 May, 2014).
   Google Scholar
• SPIROLA Software. Available from: http://www.cdc.gov/niosh/topics/spirometry/spirola-software.html (accessed 1 February, 2015).
   Google Scholar
• Tang W, Kowgier M, Loth DW, Soler Artigas M, Joubert BR, Hodge E, Gharib SA, Smith AV, Ruczinski I, Gudnason V, Mathias RA, Harris TB, Hansel NN, Launer LJ, Barnes KC, Hansen JG, Albrecht E, Aldrich MC, Allerhand M, Barr RG, Brusselle GG, Couper DJ, Curjuric I, Davies G, Deary IJ, Dupuis J, Fall T, Foy M, Franceschini N, Gao W, Gläser S, Gu X, Hancock DB, Heinrich J, Hofman A, Imboden M, Ingelsson E, James A, Karrasch S, Koch B, Kritchevsky SB, Kumar A, Lahousse L, Li G, Lind L, Lindgren C, Liu Y, Lohman K, Lumley T, McArdle WL, Meibohm B, Morris AP, Morrison AC, Musk B, North KE, Palmer LJ, Probst-Hensch NM, Psaty BM, Rivadeneira F, Rotter JI, Schulz H, Smith LJ, Sood A, Starr JM, Strachan DP, Teumer A, Uitterlinden AG, Völzke H, Voorman A, Wain LV, Wells MT, Wilk JB, Williams OD, Heckbert SR, Stricker BH, London SJ, Fornage M, Tobin MD, O'Connor GT, Hall IP, Cassano PA. Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function. PLoS One 2014; 9(7):e100776. doi: 10.1371/journal.pone.0100776.
   Google Scholar
• Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, Wilk JB, Vonk JM, Thun GA, Siroux V, Nadif R, Monier F, Gonzalez JR, Wjst M, Heinrich J, Loehr LR, Franceschini N, North KE, Altmüller J, Koppelman GH, Guerra S, Kronenberg F, Lathrop M, Moffatt MF, O'Connor GT, Strachan DP, Postma DS, London SJ, Schindler C, Kogevinas M, Kauffmann F, Jarvis DL, Demenais F, Probst-Hensch NM. Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol 2012; 129(5):1218–1228. doi:10.1016/j.jaci.2012.01.074.
   Google Scholar